The latest news and views from bridge therapeutics

04/23/19 Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors

Bridge Therapeutics is pleased to announce the addition of Edward J. Minskoff to its board of directors. 

April 23, 2019 

As a major Manhattan real estate acquirer and developer of 40 million square feet of commercial space, Edward J. Minskoff brings decades of financial and business experience to Bridge. On joining Bridge’s board, Mr. Minskoff commented, “I see Bridge improving the healthcare of millions as it becomes a highly successful pharmaceutical company.”

Read the full article here 

02/01/19 Medical Leaders: Elevate Evidence Over Bias in Opioid Disorder Treatment

The case for buprenorphine in the treatment of opioid addiction is overwhelming, yet stigmas and biases still remain leading to inadequate treatment of those battling addiction. “Basing medical decisions on beliefs about medications does nothing to help the growing pool of those with [opioid use disorder], who if untreated are likely to fall victim to an overdose”, says Dr. Joshua A. Barocas, of Boston Medical Center and Boston University School of Medicine. Dr. Barocas emphasizes the need for an educational campaign to dispel the myth that someone who is taking an agonist to combat opioid addiction is not “addicted” to the medication. 

December 21, 2018

Buprenorphine for opioid addiction is the only medication with federal limits on the number of patients a doctor can treat. Even buprenorphine for the purpose of treating pain does not have a patient cap.

Read the full article here

11/07/18 Dr. Steven Passik Has Joined the Scientific Advisory Board of Bridge Therapeutics

Steve Passik PhD, a recognized leader and researcher in pain management and addiction joins Bridge Therapeutics Scientific Advisory Board.

November 7, 2018

Dr. Passik has been a Principal Investigator for numerous clinical trials funded by both pharmaceutical companies and government funded organizations. The intersection of pain and addiction has been the focus for much of his teaching activities and peer reviewed articles. He has written extensively on the treatment of cancer and AIDS patient’s pain management.

Read full article here

11/02/18 Bridge Therapeutics Announces the Addition of Dr. Bob Rappaport to Its Scientific Advisory Board

As their newest member, Dr. Bob Rappaport brings decades of drug approval experience to Bridge Therapeutics’ Scientific Advisory Board. 

November 2, 2018 

Dr. Rappaport spent 20 years at the Food and Drug Administration, with the last 12 years as Director of the Anesthesia, Analgesia, and Addiction Products Division at the Center for Drug Evaluation and Research. There he oversaw the approvals of drug products for that sector. Prior to his retirement, Dr. Rappaport received the FDA Lifetime Achievement Award.

Read the full article here

10/31/18 Bridge Therapeutics is Selected as a Finalists for the RESI 2018 Innovation Challenge

Bridge Therapeutics will present a poster presentation at the RESI Conference November 4, 2018, in New York.

October 31, 2018

Bridge Therapeutics has been selected by Life Science Nation’s internal scientific review board to be part of the Innovation Challenge presenting its technology in an exhibition-style format throughout the full-day RESI Conference on November 4, 2018, in New York. Being a Finalist gains Bridge additional exposure to investors and potential partners by showcasing its company and products through a dedicated poster in the Exhibit Hall.

Read the full article here


10/18/18 Panel: Buprenorphine ‘Can Give Patients Their Lives Back’

Ruth Potee, M.D., of Greenfield, Mass., said that when buprenorphine first became available in 2002, there was an expectation that it would be widely used in primary care because addiction is a chronic condition. “By 2010, only 2 percent of primary care physicians were prescribing it,” she said. “That was a massive failure.”

October 16, 2018 

Dr. David O’Gurek, associate professor in the Department of Family and Community Medicine at the Lewis Katz School of Medicine at Temple University of Philadelphia said stigma is one of the challenges of overcoming substance abuse disorder. He said buprenorphine can help by giving people more control.

Read the full article here

09/21/18 Dr. Bob Raffa Joins Bridge Therapeutics’ Scientific Advisory Board Bringing Decades of Research and Experience

Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. 

September 21, 2018 

Dr. Raffa is a global leader in pharmacology, with over 40 years of preclinical research on drug abuse and analgesic drug discovery. He has held many prestigious leadership roles, including Co-Leader for analgesic drug discovery at Johnson & Johnson where he attained the level of Research Fellow, as well as being Professor Emeritus at Temple University School of Pharmacy.

Read the full article here

09/04/18 Bridge Therapeutics Team to Speak on Tackling a Key Source of the Opioid Crisis

Dr. Greg Sullivan, Chief Scientific Officer, Dr. Dave Bergstrom. Chief Operations Officer, and Tim Peara of will be speaking about how Bridge Therapeutics’ lead investigational drug could be a key part of ending the opioid crisis.

September 4, 2018

Each year 70 million Americans will take an opioid for pain. Of these, 17 million take a strong opioid daily. It is these 17 million patients who are most at risk of addiction disorders leasing to shattered relationships, overdoes, and possibly death. 70% of opioid overdose victims started by abusing pain medication. A key part to ending the Opioid Crisis will be providing a safer therapy than opioids for chronic pain.

Read the full article here

08/21/18 Medication-Assisted Treatments Underused in Patients With Opioid Use Disorder

“A great part of the tragedy of this opioid crisis is that, unlike in previous such crises America has seen, we now possess effective treatment strategies that could address it and save lives,” Nora Volkow, MD, the director of the National Institute on Drug Abuse, wrote in an editorial accompanying the study (Ann Intern Med 2018 Jun 19). “Yet tens of thousands of people die each year because they have not received these treatments.”  

August 20, 2018 

According to the National Institutes of Health–funded study, adults prescribed buprenorphine had a decreased mortality rate of 38%, compared with patients not receiving any medication-assisted treatment over the one-year study period.

Read the full article here

08/17/18 To fight the opioid crisis, the US needs to look at what works

In this article the Washington Examiner discusses how buprenorphine/naloxone combination should be readily available and could act as a key defense against the on going opioid problem in the U.S.

August 16, 2018

Key to understanding how buprenorphine helps is an understanding of the difference between physical dependence and addiction. This can be a confusing distinction, as the terms are sometimes used interchangeably. Addiction is essentially an uncontrollable craving and an inability to control use. Dependence, on the other hand, is the term used to describe the physical reliance on opioids.

Read full article here


For more information about Bridge Therapeutics please contact us today using the form below.